Should we use intensive hypoglycemic treatment in patients with advanced type 2 diabetes?

Polskie Archiwum Medycyny Wewnetrznej

Volumn 124, Issue 12, 2014, Pages 657-658

  Maraka, Spyridoula ^a   Morey Vargas, Oscar L ^a   Montori, Victor M ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; HEMOGLOBIN A1C; INSULIN; METFORMIN; GLYCOSYLATED HEMOGLOBIN;

BODY WEIGHT; CARDIOVASCULAR RISK; DEATH; EDITORIAL; GLYCEMIC CONTROL; HEALTH CARE; HEART INFARCTION; HUMAN; INTENSIVE CARE; LASER COAGULATION; LIFESTYLE MODIFICATION; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PLEIOTROPY; DIABETES MELLITUS, TYPE 2; TREATMENT OUTCOME;

DIABETES MELLITUS, TYPE 2; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; TREATMENT OUTCOME;

EID: 84919961330     PISSN: 00323772     EISSN: 18979483     Source Type: Journal    
DOI: 10.20452/pamw.2544     Document Type: Editorial

References (12)

1. Patel A, MacMahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008; 358: 2560-2572.
2. Zoungas S, Chalmers J, Neal B, et al. Follow-up of blood-pressure lowering and glucose control in type 2 diabetes. N Engl J Med. 2014; 371: 1392-1406.
3. Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008; 358: 2545-2559.
4. Ismail-Beigi F, Craven T, Banerji MA, et al. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: An analysis of the ACCORD randomised trial. Lancet. 2010; 376: 419-430.
5. Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009; 360: 129-139.
6. Bassler D, Briel M, Montori VM, et al. Stopping randomized trials early for benefit and estimation of treatment effects: Systematic review and meta-regression analysis. JAMA. 2010; 303: 1180-1187.
7. UK Prospective Diabetes Study (UKPDS). VIII. Study design, progress and performance. Diabetologia. 1991; 34: 877-890.
8. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998; 352: 837-853.
9. Anfossi G, Russo I, Bonomo K, Trovati M. The cardiovascular effects of metformin: Further reasons to consider an old drug as a cornerstone in the therapy of type 2 diabetes mellitus. Curr Vasc Pharmacol. 2010; 8: 327-337.
10. Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008; 359: 1577-1589.
11. Standards of medical care in diabetes -2014. Diabetes Care. 2014; 37 Suppl 1: S14-80.
12. Mullan RJ, Montori VM, Shah ND, et al. The diabetes mellitus medication choice decision aid: A randomized trial. Arch Intern Med. 2009; 169: 1560-1568.